Zoetis UK and Ireland Brexit Position Statement

Correcting nested headings

Correcting nested headings

Correcting nested headings

We have already been responding to enquiries so please find below our current statement;

“As a result of the UK vote to leave the EU Zoetis would like to reassure those who supply, prescribe or use our products that we are continually monitoring the situation and plan to minimise the impact. Zoetis is making plans to ensure adequate stock exists in its supply chain and warehouse in the UK to mitigate any issues that may arise post Brexit. This includes ensuring sufficient medicines are in the UK through bringing forward some planned deliveries and exploring back up supply routes in case of port delays.  We continue to work closely with the VMD and other agencies to remain at the leading edge in managing and influencing Brexit plans to facilitate the continuing acceptability and supply of stock made and released in the EU.  We remain confident our planning will enable us to manage any Brexit issues and ensure that business and supply remains normal and our customers will not notice any impact on medicines availability.  We very much acknowledge the cooperative role and position the VMD are taking in helping the animal health industry maintain supply and encourage customers to work closely with us on demand planning as we will have already made provisions.”